Tianshu Pharmaceutical Selected as 2025 Hubei Science and Technology Innovation "New Species" Gazelle Enterprise

Recently, the Hubei Provincial Department of Science and Technology announced the list of proposed enterprises to be included in Hubei's 2025 Science and Technology Innovation "New Species" Enterprise Database. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) stood out with its outstanding scientific and technological innovation capabilities and high growth potential, successfully being selected as a Hubei Science and Technology Innovation "New Species" Gazelle Enterprise. This signifies that Tianshu Pharmaceutical has received high recognition and affirmation from the government in terms of growth rate, innovation capability, professional fields, and development potential.

　　Tianshu Pharmaceutical has always attached great importance to scientific and technological innovation, continuously promoting the R&D and introduction of cutting-edge engineering technologies. Currently, Tianshu Pharmaceutical has achieved more than 30 scientific and technological innovation results, including 5 invention patents, 28 utility model patents, and 2 PCT international patents. It has been successfully selected as a Hubei Provincial "Specialized, Refined, Characteristic, and Innovative" Small and Medium-sized Enterprise and a Hubei Provincial Technology-based Small and Medium-sized Enterprise. It has also been approved to establish the Hubei Provincial Small and Medium-sized Enterprise Technology Center and the Hubei Provincial High-end API and Pharmaceutical Intermediate CDMO R&D and Production Pilot Test Platform, etc. Additionally, it has successfully passed the "Three-in-One" certification for GB/T19001-2016/ISO Quality Management System, GB/T24001-2016/ISO Environmental Management System, and GB/T45001-2020/ISO Occupational Health and Safety Management System.

　　In the future, Tianshu Pharmaceutical will continue to make efforts, increase investment in R&D and innovation, continuously enhance technological innovation capabilities, adhere to independent innovation, strive to improve the company's market competitiveness with differentiated technology as the core, and strive to become a higher-level science and technology innovation "New Species" enterprise.